Mid Pharmaceuticals

Ipca Laboratories Ltd.

IPCALAB

Market Cap
₹47,982 Cr.
P/E
42.05

Ipca Laboratories Ltd.

  • Ipca Laboratories
  • Ajanta Pharma
  • Glaxosmithkline Phar
  • TJI Pharma

FAQs on Ipca Laboratories Ltd. Shareprice

Ipca Laboratories has given lower returns compared to its competitors.
Ipca Laboratories has grown at ~12.49% over the last 5yrs while peers have grown at a median rate of 18.9%

Ipca Laboratories is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Ipca Laboratories is 42.05, while 3 year average PE is 44.7.
Also latest EV/EBITDA of Ipca Laboratories is 24.32 while 3yr average is 23.03.

View FAQ's On Business

Growth Table

  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Glaxosmithkline Phar

Balance Sheet

  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Glaxosmithkline Phar

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Glaxosmithkline Phar

Cash Flow

  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Glaxosmithkline Phar

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Glaxosmithkline Phar

Quarterly Results

  • Ipca Laboratories Ltd.
  • Ajanta Pharma
  • Glaxosmithkline Phar

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Ipca Laboratories Ltd. Financials

Balance sheet of Ipca Laboratories is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Ipca Laboratories is decreasing.
Latest net debt of Ipca Laboratories is -₹420.55 Crs as of Mar-26.
This is less than Mar-25 when it was ₹616 Crs.

Yes, profit is increasing.
The profit of Ipca Laboratories is ₹1,141 Crs for Mar 2026, ₹738 Crs for Mar 2025 and ₹547 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Ipca Laboratories latest dividend payout ratio is 13.34% and 3yr average dividend payout ratio is 15.21%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech